155 related articles for article (PubMed ID: 37345121)
1. Assessing Therapeutic Response to Radium-223 with an Automated Bone Scan Index among Metastatic Castration-Resistant Prostate Cancer Patients: Data from Patients in the J-RAP-BSI Trial.
Kitajima K; Kuyama J; Kawahara T; Suga T; Otani T; Sugawara S; Kono Y; Tamaki Y; Seko-Nitta A; Ishiwata Y; Ito K; Toriihara A; Watanabe S; Hosono M; Miyake H; Yamamoto S; Sasaki R; Narita M; Yamakado K
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345121
[TBL] [Abstract][Full Text] [Related]
2. Assessing Radiographic Response to
Anand A; Trägårdh E; Edenbrandt L; Beckman L; Svensson JH; Thellenberg C; Widmark A; Kindblom J; Ullén A; Bjartell A
J Nucl Med; 2020 May; 61(5):671-675. PubMed ID: 31586004
[TBL] [Abstract][Full Text] [Related]
3. Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment-Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) Trial.
Kitajima K; Igeta M; Kuyama J; Kawahara T; Suga T; Otani T; Sugawara S; Kono Y; Tamaki Y; Seko-Nitta A; Ishiwata Y; Ito K; Toriihara A; Watanabe S; Hosono M; Miyake H; Yamamoto S; Narita M; Daimon T; Yamakado K
Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1487-1498. PubMed ID: 36539508
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of automated bone scan index for predicting overall survival among bone metastatic castration resistant prostate cancer patients treated with radium-223.
Miyoshi Y; Tsutsumi S; Kawahara T; Yasui M; Uemura K; Yoneyama S; Yokomizo Y; Hayashi N; Yao M; Uemura H
BJUI Compass; 2021 Jan; 2(1):24-30. PubMed ID: 35474664
[TBL] [Abstract][Full Text] [Related]
5. Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Armstrong AJ; Anand A; Edenbrandt L; Bondesson E; Bjartell A; Widmark A; Sternberg CN; Pili R; Tuvesson H; Nordle Ö; Carducci MA; Morris MJ
JAMA Oncol; 2018 Jul; 4(7):944-951. PubMed ID: 29799999
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel.
Uemura K; Miyoshi Y; Kawahara T; Ryosuke J; Yamashita D; Yoneyama S; Yokomizo Y; Kobayashi K; Kishida T; Yao M; Uemura H
BMC Cancer; 2018 May; 18(1):501. PubMed ID: 29716525
[TBL] [Abstract][Full Text] [Related]
7. Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide.
Anand A; Morris MJ; Larson SM; Minarik D; Josefsson A; Helgstrand JT; Oturai PS; Edenbrandt L; Røder MA; Bjartell A
EJNMMI Res; 2016 Dec; 6(1):23. PubMed ID: 26960325
[TBL] [Abstract][Full Text] [Related]
8. Prediction of survival benefit using an automated bone scan index in patients with castration-resistant prostate cancer.
Mitsui Y; Shiina H; Yamamoto Y; Haramoto M; Arichi N; Yasumoto H; Kitagaki H; Igawa M
BJU Int; 2012 Dec; 110(11 Pt B):E628-34. PubMed ID: 22788759
[TBL] [Abstract][Full Text] [Related]
9. Automated Bone Scan Index as an Imaging Biomarker to Predict Overall Survival in the Zometa European Study/SPCG11.
Reza M; Wirth M; Tammela T; Cicalese V; Veiga FG; Mulders P; Miller K; Tubaro A; Debruyne F; Patel A; Caris C; Witjes W; Thorsson O; Wollmer P; Edenbrandt L; Ohlsson M; Trägårdh E; Bjartell A
Eur Urol Oncol; 2021 Feb; 4(1):49-55. PubMed ID: 31186177
[TBL] [Abstract][Full Text] [Related]
10.
Fosbøl MØ; Petersen PM; Kjaer A; Mortensen J
J Nucl Med; 2018 Apr; 59(4):596-602. PubMed ID: 28864632
[TBL] [Abstract][Full Text] [Related]
11. Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer.
Saylor PJ; Otani K; Balza R; Ukleja J; Pleskow H; Fisher R; Kusaka E; Otani YS; Badusi PO; Smith MR; Meneely E; Olivier K; Lowe AC; Toner M; Maheswaran S; Haber DA; Yeap BY; Lee RJ; Miyamoto DT
JCO Precis Oncol; 2024 Feb; 8():e2300230. PubMed ID: 38354328
[TBL] [Abstract][Full Text] [Related]
12. Radium-223 dichloride treatment in metastatic castration-resistant prostate cancer in Finland: A real-world evidence multicenter study.
Hyväkkä A; Kääriäinen OS; Utriainen T; Löyttyniemi E; Mattila K; Reinikainen P; Sormunen J; Jääskeläinen M; Auvinen P; Minn H; Sundvall M
Cancer Med; 2023 Feb; 12(4):4064-4076. PubMed ID: 36156455
[TBL] [Abstract][Full Text] [Related]
13. Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone Acetate (Zytiga) in Clinical Practice.
Reza M; Ohlsson M; Kaboteh R; Anand A; Franck-Lissbrant I; Damber JE; Widmark A; Thellenberg-Karlsson C; Budäus L; Steuber T; Eichenauer T; Wollmer P; Edenbrandt L; Trägårdh E; Bjartell A
Eur Urol Focus; 2016 Dec; 2(5):540-546. PubMed ID: 28723520
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.
Isaacsson Velho P; Qazi F; Hassan S; Carducci MA; Denmeade SR; Markowski MC; Thorek DL; DeWeese TL; Song DY; Tran PT; Eisenberger MA; Antonarakis ES
Eur Urol; 2019 Aug; 76(2):170-176. PubMed ID: 30293905
[TBL] [Abstract][Full Text] [Related]
15. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
Liu AJ; Kosiorek HE; Ueberroth BE; Jaeger E; Ledet E; Kendi AT; Tzou K; Quevedo F; Choo R; Moore CN; Ho TH; Singh P; Keole SR; Wong WW; Sartor O; Bryce AH
Prostate; 2022 Sep; 82(12):1202-1209. PubMed ID: 35652618
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.
Matsubara N; Nagamori S; Wakumoto Y; Uemura H; Kimura G; Yokomizo A; Kikukawa H; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Tsutsui H; Uemura H
Int J Clin Oncol; 2018 Feb; 23(1):173-180. PubMed ID: 28770408
[TBL] [Abstract][Full Text] [Related]
17. Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer.
McNamara MA; Oyekunle T; Chin BB; Oldan J; Anand A; Ritz M; Shantzer L; Anand M; Armstrong AJ; George DJ
Prostate; 2019 Jul; 79(10):1106-1116. PubMed ID: 31045266
[TBL] [Abstract][Full Text] [Related]
18. ALP bouncing and LDH normalization in bone metastatic castration-resistant prostate cancer patients under therapy with Enzalutamide: an exploratory analysis.
Schlack K; Krabbe LM; Rahbar K; Isenberg K; Semjonow A; Schrader AJ; Boegemann M
Transl Androl Urol; 2021 Oct; 10(10):3986-3999. PubMed ID: 34804841
[TBL] [Abstract][Full Text] [Related]
19. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy.
Sonpavde G; Pond GR; Berry WR; de Wit R; Armstrong AJ; Eisenberger MA; Tannock IF
Urol Oncol; 2012 Sep; 30(5):607-13. PubMed ID: 20888271
[TBL] [Abstract][Full Text] [Related]
20. Automated Bone Scan Index to Optimize Prostate Cancer Working Group Radiographic Progression Criteria for Men With Metastatic Castration-Resistant Prostate Cancer.
Anand A; Heller G; Fox J; Danila DC; Bjartell A; Edenbrandt L; Larson SM; Scher HI; Morris MJ
Clin Genitourin Cancer; 2022 Jun; 20(3):270-277. PubMed ID: 35279418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
